Compounds > ag-1296

ag-1296 and sb 203580

ag-1296 has been researched along with sb 203580 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dai, JR; Deretey, E; Foster, JE; Ng, W; Pasternak, A; Redden, PR; Reid, N; Slon-Usakiewicz, JJ; Toledo-Sherman, L1
Dai, JR; Deretey, E; Foster, JE; Liao, LC; Ng, W; Pasternak, A; Redden, PR; Reid, N; Slon-Usakiewicz, JJ; Toledo-Sherman, L; Uger, MD1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A1
Buresi, MC; Buret, AG; Hollenberg, MD; MacNaughton, WK1

Other Studies

5 other study(ies) available for ag-1296 and sb 203580

ArticleYear
Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 1. Comparison with conventional ELISA.
    Journal of medicinal chemistry, 2004, Oct-07, Volume: 47, Issue:21

    Topics: Chromatography, Affinity; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Ligands; Mass Spectrometry; Models, Molecular; Receptor, EphB2

2004
Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening.
    Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9

    Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Chromatography, Affinity; Databases, Factual; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds; Humans; Mass Spectrometry; Models, Molecular; Molecular Weight; Naphthoquinones; Phosphorylation; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship; Receptor, EphB2; Sulfides

2005
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

    Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013
Activation of proteinase-activated receptor 1 stimulates epithelial chloride secretion through a unique MAP kinase- and cyclo-oxygenase-dependent pathway.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2002, Volume: 16, Issue:12

    Topics: Androstadienes; Butadienes; Cell Line; Chlorides; Epithelial Cells; Humans; Imidazoles; Indoles; Maleimides; Mitogen-Activated Protein Kinases; Nitriles; Nitrobenzenes; Phospholipases A; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor, PAR-1; Receptors, Thrombin; Signal Transduction; Sulfonamides; Thrombin; Tyrphostins; Wortmannin

2002